News and Trends 12 Mar 2019 Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss… March 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2020 Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease …approach to Alexion and the other antibody developers, whose drugs require intravenous injection. The company also targets another rare neuromuscular condition, myasthenia gravis, with the same drug candidate. “Chord Therapeutics… October 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 31 May 2019 This Biotech Treats a Neurological Autoimmune Disorder Using DNA …begin clinical trials in 2023. Pure Biologics also has a separate program developing an antibody drug that binds two targets at once, called a bispecific antibody. Although there are other… May 31, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2018 Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M …cells called regulatory T cells. These cells hold back the immune system from attacking tumors, thus the antibody helps the patient’s immune system to fight the cancer. The antibody has… September 28, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Maxion Therapeutics raises $16M to target GPCRs …co-founded CAT (acquired by AstraZeneca for £700 million) and IONTAS (acquired by FairJourney Biologics). At CAT, McCafferty co-invented antibody phage display, the technology used to discover the world’s best-selling drug,… February 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Positive results from Eisai and Biogen Alzheimer’s trial …antibody. It met the primary endpoint and all key secondary endpoints with highly statistically significant results. Lecanemab is an investigational humanized monoclonal antibody for AD that is the result of… September 29, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Feb 2024 Future of cancer treatment: what will therapy look like in 2034? …the clinic. Maher expects antibody-based therapeutics to continue to yield new drugs like immunomodulatory agents and antibody drug conjugates “that deliver ever more powerful poisons in a selective manner to… February 5, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2025 Life sciences in Wales: biotechs in the scene in 2025 …Antiverse Founded in 2017 Technology: Antibody discovery and development Latest funding: $4.6 million investment AI has accelerated innovation in the world of biotech. Over the years, it has bolstered antibody… June 30, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2016 Looking for outperforming cell lines ? CHOvolution is an all-in-one kit for GMP Bioproduction …therapeutic antibody’s development due to the similarity of the cells to human cells (e.g. folding, glycosylation etc). For example, CHO-K1-based cell lines, derived from the ovarian cells of the Chinese… November 19, 2016 - 4 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022 ImCheck raises €96M in funding round …The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development for liquid and solid tumors. … June 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus …long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly by AstraZeneca and Sanofi… November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Turning the tide: recent advancements in childhood cancer research …the formation of a tumor. As neuroblastomas predominantly express the molecule GD2, Renaissance’s lead candidate Hu14.18 is a humanized, anti-GD2 antibody. When an anti-GD2 antibody is combined with chemotherapy in… February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email